Imcyse is a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases. The company’s unique technology platform can address a wide range of autoimmune and immunologic diseases. Imotopes™ are modified synthetic peptides, which specifically block improper immune activity. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no effective therapeutic alternative and has the potential to cure patients without impairing their immune defenses.

Our vision is to become a leader in the field of active specific immunotherapy and to prevent, stop and potentially cure autoimmune diseases. 

Headquartered in Liège, Belgium, Imcyse was founded as a spin-off of the Catholic University of Leuven (KULeuven). Imcyse’s Imotope™ technology platform is protected by a robust, international intellectual property portfolio.

Our lead Imotope™, IMCY-0098, is in phase 2 clinical testing for early onset type 1 diabetes.


Biotechnology

Life Sciences

Therapeutics

Imcyse SA

Denis Bedoret

Jean van Rampelbergh

Antoon van Oosterhout

Hugues Wallemacq

Andrew Mackie

The Management team at Imcyse SA is responsible for overseeing the strategic direction and operational execution of the company. They ensure that the company's vision to become a leader in active specific immunotherapy is realized by managing clinical development, intellectual property, business partnerships, and quality assurance. This team collaborates closely to drive the innovation and commercialization of the Imotope™ technology platform, while ensuring regulatory compliance, facility maintenance, and IT support to promote the development and clinical testing of breakthrough treatments for severe autoimmune diseases.

Management

Leadership Team

Scientific Research and Development

Management

About

Team members

Other teams at Imcyse SA

Leadership Team

Scientific Research and Development